Aniplus Inc. (KOSDAQ:310200)
3,060.00
+35.00 (1.16%)
At close: Jan 29, 2026
Aniplus Revenue
Aniplus had revenue of 55.71B KRW in the quarter ending September 30, 2025, with 44.26% growth. This brings the company's revenue in the last twelve months to 146.00B, up 14.64% year-over-year. In the year 2024, Aniplus had annual revenue of 130.98B with 17.63% growth.
Revenue (ttm)
146.00B
Revenue Growth
+14.64%
P/S Ratio
1.06
Revenue / Employee
2.98B
Employees
49
Market Cap
155.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.98B | 19.63B | 17.63% |
| Dec 31, 2023 | 111.35B | 53.53B | 92.59% |
| Dec 31, 2022 | 57.82B | 8.78B | 17.90% |
| Dec 31, 2021 | 49.04B | 33.15B | 208.68% |
| Dec 31, 2020 | 15.89B | -2.47B | -13.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kyung Dong Pharmaceutical | 193.64B |
| Com2uS Holdings | 91.57B |
| D&C Media | 87.18B |
| EXEM Co., Ltd. | 64.21B |
| DreamCIS | 62.06B |
| Samik Pharmaceutical Company LTD. | 58.88B |
| WSI Co., Ltd. | 50.34B |
| CG MedTech | 45.59B |